246 related articles for article (PubMed ID: 28242811)
1. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.
Mustachio LM; Lu Y; Tafe LJ; Memoli V; Rodriguez-Canales J; Mino B; Villalobos PA; Wistuba I; Katayama H; Hanash SM; Roszik J; Kawakami M; Cho KJ; Hancock JF; Chinyengetere F; Hu S; Liu X; Freemantle SJ; Dmitrovsky E
Mol Cancer Res; 2017 Jul; 15(7):905-914. PubMed ID: 28242811
[No Abstract] [Full Text] [Related]
2. The ISG15-specific protease USP18 regulates stability of PTEN.
Mustachio LM; Kawakami M; Lu Y; Rodriguez-Canales J; Mino B; Behrens C; Wistuba I; Bota-Rabassedas N; Yu J; Lee JJ; Roszik J; Zheng L; Liu X; Freemantle SJ; Dmitrovsky E
Oncotarget; 2017 Jan; 8(1):3-14. PubMed ID: 27980214
[TBL] [Abstract][Full Text] [Related]
3. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis.
Chen Z; Zheng L; Chen Y; Liu X; Kawakami M; Mustachio LM; Roszik J; Ferry-Galow KV; Parchment RE; Liu X; Andresson T; Duncan G; Kurie JM; Rodriguez-Canales J; Liu X; Dmitrovsky E
Cancer Biol Ther; 2022 Dec; 23(1):265-280. PubMed ID: 35387560
[TBL] [Abstract][Full Text] [Related]
4. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.
Mustachio LM; Lu Y; Kawakami M; Roszik J; Freemantle SJ; Liu X; Dmitrovsky E
Cancer Res; 2018 Feb; 78(3):587-592. PubMed ID: 29343520
[TBL] [Abstract][Full Text] [Related]
6. The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth.
Liu X; Lu Y; Chen Z; Liu X; Hu W; Zheng L; Chen Y; Kurie JM; Shi M; Mustachio LM; Adresson T; Fox S; Roszik J; Kawakami M; Freemantle SJ; Dmitrovsky E
Mol Cancer Res; 2021 Apr; 19(4):667-677. PubMed ID: 33380466
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the ubiquitin protease UBP43 as an antineoplastic target.
Guo Y; Chinyengetere F; Dolinko AV; Lopez-Aguiar A; Lu Y; Galimberti F; Ma T; Feng Q; Sekula D; Freemantle SJ; Andrew AS; Memoli V; Dmitrovsky E
Mol Cancer Ther; 2012 Sep; 11(9):1968-77. PubMed ID: 22752428
[TBL] [Abstract][Full Text] [Related]
9. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
[TBL] [Abstract][Full Text] [Related]
10. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
11. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
12. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
[TBL] [Abstract][Full Text] [Related]
13. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
[No Abstract] [Full Text] [Related]
14. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
15. Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.
Schuster K; Venkateswaran N; Rabellino A; Girard L; Peña-Llopis S; Scaglioni PP
Mol Cancer Res; 2014 Jun; 12(6):912-23. PubMed ID: 24618618
[TBL] [Abstract][Full Text] [Related]
16. Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras
Kumar G; Madka V; Singh A; Farooqui M; Stratton N; Lightfoot S; Mohammed A; Rao CV
Neoplasia; 2021 Jun; 23(6):574-583. PubMed ID: 34091121
[TBL] [Abstract][Full Text] [Related]
17. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
18. CD44 promotes Kras-dependent lung adenocarcinoma.
Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
[TBL] [Abstract][Full Text] [Related]
19. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
20. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
